Analysts Offer Insights on Healthcare Companies: MEI Pharma (NASDAQ: MEIP) and T2 Biosystems (NASDAQ: TTOO)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MEI Pharma (MEIPResearch Report) and T2 Biosystems (TTOOResearch Report) with bullish sentiments.

MEI Pharma (MEIP)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on MEI Pharma, with a price target of $10. The company’s shares closed yesterday at $2.66.

Fein commented:

“ASCO Intermittent dosing decreases toxicity while maintaining efficacy. The data presented at ASCO reinforce our positive view on ME-401’s potential in B-cell lymphomas, and lends additional evidence supporting the intermittent schedule (IS) as enhancing the drug’s clinical profile. We highlight the following data points that speak to the advantages of IS: (1) IS reduced toxicity. The rate of Grade 3 diarrhea/colitis was 16.1% in CS vs. 8.7% in IS, and the rate of Grade 3 rash was 12.9% in CS vs. 0% in IS. Meanwhile, treatment discontinuation rate due to adverse events (AEs) was 13% in CS vs. 0% in IS; (2) IS is sufficient to maintain treatment efficacy.”

According to TipRanks.com, Fein is a 2-star analyst with an average return of 0.3% and a 39.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on MEI Pharma is a Moderate Buy with an average price target of $8.50.

See today’s analyst top recommended stocks >>

T2 Biosystems (TTOO)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on T2 Biosystems today and set a price target of $10. The company’s shares closed yesterday at $1.64, close to its 52-week low of $1.60.

According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -26.4% and a 35.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aslan Pharmaceuticals Ltd, Seelos Therapeutics Inc, and Eyenovia Inc.

Currently, the analyst consensus on T2 Biosystems is a Strong Buy with an average price target of $10.50, which is a 540.2% upside from current levels. In a report issued on May 24, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $10 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.